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Summary Background This study evaluated the safety, toler-
ability, pharmacokinetics, immunogenicity and antitumor activ-
ity of single and multiple doses of nivolumab in Japanese pa-
tients with malignant solid tumors. Subjects and Methods This
was an open-label, dose-escalation study in 17 patients with
advanced solid tumors with a life expectancy of ≥3 months.
Patients were observed for 3 weeks after a single dose of
nivolumab at 1, 3, 10 or 20 mg/kg, then received the same dose
of nivolumab every 2 weeks until unacceptable toxicity or dis-
ease progression occurred. This study included a maximum
dose of 20 mg/kg, which is the highest dose of nivolumab
evaluated to date. The maximum dose was 10 mg/kg in previ-
ous studies. Results The commonest adverse drug reaction was
lymphopenia, which occurred in 10 (58.8%) patients, including
two (11.8%) with Grade ≥3 events. No dose-limiting toxicities
(DLTs) were observed up to the maximum dose of 20 mg/kg.
The area under the concentration–time curve from time 0 to the
last measurable concentration was linear up to 20 mg/kg. The
maximum concentration showed dose-dependency up to
10 mg/kg, but not between 10 and 20 mg/kg. One durable
complete response and two partial responses were observed.
Conclusions Nivolumab at doses of 1–20 mg/kg was not
associated with DLTs, and it was generally well tolerated at
doses of up to 20 mg/kg in Japanese patients with advanced
solid tumors.
Keywords Phase I study . Nivolumab . Immune checkpoint
inhibitor . Pharmacokinetics
Introduction
Cancer accounted for 330,000 deaths in Japan—approximate-
ly 30% of all deaths—in 2010 [1]. Despite advances in cancer
treatment, the morbidity and mortality rates associated with
some types of cancer are expected to continue to increase [2].
Immunotherapeutic agents, such as biologics, which use
the body’s own immunity to eliminate tumors or directly tar-
get tumors, have been under investigation for several decades.
In recent years, these agents have been included alongside
surgery, radiation and chemotherapy in the treatment of many
types of cancer [3, 4]. More recently, vaccine therapies using
cancer antigens or dendritic cells have been studied, but their
response rates were as low as 2.6%, partly because of the
expression of molecules (e.g., cytokines and co-stimulators)
that suppress immunological activity on regulatory lympho-
cytes and cancer cells themselves [5].
Programmed death-1 (PD-1) (also known as CD279) is a
CD28 family receptor that is expressed on activated lympho-
cytes (T cells, B cells and NKT cells) and myeloid cells. PD-1
and its ligands defend against self-reactive effector T cells by
promoting the development and function of regulatory T cells
and directly inhibiting potentially pathogenic self-reactive pe-
ripheral T cells [6]. PD-1 ligands are expressed on antigen-
presenting cells (APCs) and parenchymal cells. PD-1 ligands
on APCs induce immunological tolerance by switching off
autoreactive T cells, while ligands expressed on parenchymal
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cells suppress effector T cells, thus maintaining peripheral
tolerance by preventing tissue destruction [7]. PD-1, its li-
gands (e.g., PD-L1), or both are overexpressed in many auto-
immune diseases, including inflammatory bowel disease,
rheumatoid arthritis and type 1 diabetes [6].
PD-1 deficiency in mice leads to the development of vari-
ous autoimmune disorders, such as dilated cardiomyopathy
associated with autoantibody production in BALB/c mice,
systemic lupus erythematosus-like glomerular nephritis and
arthritis in C57BL/6 mice, myocarditis associated with gener-
ation of autoantibody in MRL mice, and accelerated type 1
diabetes in non-obese diabetic mice, suggesting that PD-1 is
involved in the suppression of autoimmune reactions [7, 8].
PD-L1 expression by tumor cells may induce and maintain
regulatory Tcells in the tumor, allowing tumor progression by
enhanced suppression of antitumor T-cell responses [9]. In
addition to APCs, PD-1 ligands are expressed in various hu-
man cancer tissues [9], and PD-L1 expression in resected can-
cer tissues was correlated with postoperative survival time in
ovarian cancer [10], malignant melanoma [11], esophageal
cancer [12], renal cell carcinoma (RCC) [13], pancreatic can-
cer [14], and urothelial cancer [15], for example. In an exper-
iment using a murine cancer cell line, the PD-1 ligand-knock-
out murine cancer cell line (P815 cells) was attacked by cyto-
toxic T cells specific to this cancer cell line. Transfection of
this cell line with PD-L1 decreased the cells’ susceptibility to
cytotoxic Tcells. In an autologous tumor-bearing model using
the same PD-L1–transfected cancer cell line, proliferation of
the transplanted cancer cells was inhibited by anti–PD-1 anti-
body [16].
These findings suggest that the PD-1/PD-1 ligand pathway
is involved in cancer cell immunity, and that PD-1 inhibitors
are expected to be useful anticancer agents [7].
Nivolumab (Ono Pharmaceutical developmental code:
ONO-4538; Bristol-Myers Squibb [BMS] developmental
code: BMS-936558; ex-Medarex developmental code:
MDX-1106) is a fully human monoclonal antibody to human
PD-1 that was co-developed by Ono Pharmaceutical Co., Ltd.
and Medarex Inc.
Nivolumab was well tolerated when administered in a sin-
gle dose at up to 10 mg/kg, with a mean half-life (t1/2) of 17 to
24.8 days in an early Phase I study (unpublished data:
ClinicalTrials.gov [NCT00441337]). Phase II and III studies
have shown promising efficacy and tolerability of nivolumab
in advanced melanoma [17], refractory squamous non-small
cell lung cancer (NSCLC) [18], metastatic RCC [19],
platinum-resistant ovarian cancer [20], and Hodgkin’s lym-
phoma [21], for example.
The objectives of the present study were to evaluate the
safety, tolerability, and pharmacokinetics of single or multiple
doses of nivolumab in Japanese patients with malignant solid




The study enrolled patients with histologically or cytologically con-
firmed malignant solid tumors for whom standard therapy was in-
effective or for whom no appropriate treatment was available. The
inclusion criteria included age ≥20 years; Eastern Cooperative
Oncology Group (ECOG) performance status (PS) 0 or 1; measur-
able lesion; life expectancy of ≥3months; and adequate organ func-
tions (AST≤82.5 IU/L;ALT≤105 IU/L; total bilirubin≤2.4mg/dL;
creatinine ≤2.0 mg/dL).
Chemotherapy, immunotherapy (e.g., tumor vaccines and
cytokines), surgery, and radiotherapy were prohibited for
4 weeks prior to study treatment. Radiopharmaceuticals
(e.g., strontium) were prohibited for 8 weeks prior to study
treatment. No patients with primary or metastatic lesions in
the brain or meninges were included unless they were asymp-
tomatic and did not require treatment. Women of childbearing
potential and men were required to use contraception.
The major exclusion criteria included: history of severe
hypersensitivity reaction to other antibody products; adverse
drug reactions (ADRs) associated with prior treatments or
surgical therapy with a possible influence on the study out-
come; multiple primary cancers; any active autoimmune dis-
ease or documented history of any chronic or recurrent auto-
immune disease or requirement for systemic steroids or im-
munosuppressants; requirement for or a history of transplan-
tation; and failure of a fixed-dose narcotic analgesic regimen
to control bone pain associated with bone metastases.
Study design
The study was a single-center, open-label dose-escalation
study (Fig. 1). The dose-escalationmethodologywas conduct-
ed as follows. Patients were observed for 3 weeks after a
single dose of nivolumab. Eligible patients continued to re-
ceive nivolumab at the initial dose every 2 weeks until disease
progression or unacceptable toxicities were observed (up to
24 months). The dosing regimen was based on a previous
phase I single-dose study in which the mean t1/2 was 17 to
24.8 days for nivolumab at doses of 0.3 to 10 mg/kg (unpub-
lished data: ClinicalTrials.gov [NCT00441337]).
Dose-limiting toxicity (DLT) was defined as any adverse
event (AE) occurring up to 7 weeks after the first nivolumab
treatment that fulfilled any of the following criteria and for which
a causal relationship with the study drug could not be ruled out:
& Grade 4 neutropenia persisting for 7 days,
& Grade 4 thrombopenia or Grade 3 thrombopenia requiring
blood transfusion,
& Grade ≥3 non-hematological toxicities, except for the fol-
lowing toxicities:
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– Grade 4 flu-like syndrome,
– Grade ≥3 nausea, vomiting, anorexia or diarrhea that does
not resolve despite full supportive care, or,
– Grade ≥3 hyponatremia, fever, or injection site reaction
that in the investigator’s or subinvestigator’s opinion re-
quires study discontinuation.
The methodology relating to dose-escalation and DLTs is
shown in Fig. 2. If a DLTwas observed in 0/3 patients or only
1/6 patients in a step, patients could be enrolled into the next
dose step.
All ADRs were evaluated using NCI-CTCAE ver.3.
Serum concentrations of nivolumab were measured using a
validated enzyme-linked immunosorbent assay (ELISA),
which was based on a sandwich ELISA platform using a re-
combinant human PD-1/Fc chimeric protein as a capture and
mouse anti-human IgG4-alkaline phosphatase as a detector.
Serum samples were collected prior to dosing, just before
the end of the nivolumab infusion and at 2 h and 8 h post-
dose, on days 2, 3, 4, 8, 15 and 22, and at study
discontinuation.
Administration of nivolumab
The study drug administered throughout this trial was
nivolumab (ONO-4538 Intravenous Infusion 100 mg).
Patients received their assigned dose of nivolumab for the
duration of the study (1, 3, 10 or 20 mg/kg), infused intrave-
nously over 1 h, through a 0.2-μm in-line filter in a total
volume of 60 mL.
Objectives
The study was designed to evaluate the safety, tolerability, and
pharmacokinetics of nivolumab in Japanese patients with ma-
lignant solid tumors, and to investigate the pharmacological
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activity and efficacy of nivolumab. The primary objective was
to assess the safety and tolerability of nivolumab in terms of
ADRs, DLTs, laboratory parameters and vital signs. We
intended to use this information to estimate the maximum toler-
ated dose (MTD) of nivolumab for use in future studies. The
efficacy of nivolumab was assessed as an exploratory endpoint
in terms of the tumor’s response (as measured by diagnostic
imaging) and changes in tumor markers. The tumor responses
were assessed according to the RECIST guideline version 1.0.
The pharmacokinetics of nivolumab were assessed using the
serum nivolumab concentration. As exploratory endpoints, we
also investigated the following pharmacodynamic parameters:
lymphocyte subset analysis (CD3/CD4/CD8/CD19/CD56/
CD45RO/HLA-DR/PD-1); cellular immune response (CEF
peptide antigen; an antigen in which peptides derived from cy-
tomegalovirus antigen, Epstein Barr (EB) virus antigen, and
influenza virus antigen are mixed), humoral immune response
(anti-NY-ESO-1, anti-survivin and anti-p53); serum cytokines
(IL-2, IL-5, IL-6, IL-8, IL-10, IFN-g, TNF-α, TGF-β); immu-
noglobulin (antibody) (IgM, IgG1, IgG2, IgG3, IgG4 and IgA);
and tumor biopsy (optional).
The anti-nivolumab antibody titer was measured by
electrochemiluminescence. Immunohistochemical analysis
for PD-L1 was performed with anti-human CD274/PD-L1
antibody (clone: 27A2) (Medical & Biological Laboratories
Co., Ltd., Nagoya, Japan).
Data analysis
Four study populations were defined for data analysis. The
safety population comprised all patients with the target disease
who received nivolumab at least once. The pharmacokinetic
population comprised all patients compliant with good clinical
practice [GCP] criteria who received nivolumab and had suf-
ficient evaluable pharmacokinetic data. The pharmacodynam-
ic and efficacy populations comprised all patients compliant
with GCP criteria who received nivolumab and had evaluable
efficacy or pharmacodynamic data.
DLTs were evaluated during the 7-week period after the
first dose of nivolumab. ADRs (AEs for which a causal rela-
tionship with nivolumab could not be ruled out) were ana-
lyzed from the start to the end of the clinical study, and were
tabulated by system organ class, preferred term and grade. The
numbers of deaths, numbers of patients with serious ADRs,
and numbers of patients with ADRs leading to treatment dis-
continuation were also tabulated.
Pharmacokinetic parameters (maximum concentration
[Cmax], time to the maximum concentration [tmax], area under
the concentration–time curve from time 0 to the last measur-
able concentration [AUClast] and t1/2) were also analyzed.
For the pharmacodynamic analysis, the results of the lym-
phocyte subset analysis, antigen immune reactivity assays
using peripheral blood mononuclear cells, serum cytokine
and immunoglobulin (antibodies) levels, and tumor biopsy
were listed by patient after the multiple-dose phase and from
the start to the end of clinical study.
The efficacy parameters assessed at the end of the clinical
study were analyzed as follows. The frequency distributions of
best overall responses were plotted by dose step, and the num-
bers and percentages of responders were calculated. The time to
progression, progression-free survival, duration of complete re-
sponse (CR), duration of response, time to CR, and time to
Table 1 Baseline characteristics
of patients Nivolumab
1 mg/kg (n = 3) 3 mg/kg (n = 5) 10 mg/kg (n = 6) 20 mg/kg (n = 3)
Male 2 0 6 2
Female 1 5 0 1
Median age (range) 68.0 (61–74) 55.0 (34–73) 50.0 (35–74) 68.0 (64–71)
Performance status (ECOG)
0 1 1 2 0
1 2 4 4 3
Cancer type
Lung adenocarcinoma 1 2 2 0
Rectal cancer 1 1 0 1
Thymic carcinoma 0 0 2 0
Esophageal carcinoma 0 0 0 1
Melanoma 1 2 1 0
Colon cancer 0 0 0 1
Thyroid cancer 0 0 1 0
Previous treatment
Surgery 3 4 4 1
Radiotherapy 0 2 2 1
Chemotherapy 3 5 5 3
Molecular targeted therapy 2 2 3 2
Immunotherapy 1 3 1 0
Endocrine therapy 1 2 1 0
Data are n (%) unless otherwise indicated
ECOG Eastern Cooperative Oncology Group
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response were listed by patient. No statistical hypothesis tests
were performed. The overall sample size and the number of
subjects per dosage were calculated in reference to the
Guidelines for Methods of Clinical Evaluation of
Antimalignant Tumor Drugs (MHLW Notification No.
1101001 of the Evaluation and Licensing Division, PFSB dated
November 1, 2005) [22], where at least three subjects per dose
were needed to consider moving to the next dose.
Results
Patients
Seventeen patients were enrolled from September 2008 to
September 2010, and all were included in the efficacy, safety,
and pharmacokinetic analyses. There were three patients in the
1mg/kg group, five patients in the 3mg/kg group, six patients in
the 10 mg/kg group, and three patients in the 20 mg/kg group.
The baseline characteristics of the study participants are
shown in Table 1. There were 10 males and 7 females. The
median (range) age of all patients was 61.0 (34–74) years. The
cancer types are listed in Table 1. Patients had previously
received surgery (70.6%), radiotherapy (29.4%), chemothera-
py (94.1%), molecular-targeted therapy (52.9%), immuno-
therapy (29.4%), and endocrine therapy (23.5%).
Safety
ADRs occurring in two or more patients are shown in Table 2.
No DLTs were observed up to the highest dose of 20 mg/kg.
The commonest ADR was lymphopenia, which occurred
in 10 (58.8%) patients, including two (11.8%) with Grade ≥3
events. The other common ADRs included eosinophilia in
eight patients (47.1%); pyrexia in six patients (35.3%); re-
duced blood albumin and rash in five patients each (29.4%);
and ventricular extrasystoles, fatigue and increased blood uric
acid in four patients each (23.5%). One ADR (dehydration in
one patient in the 10 mg/kg group) was classified as serious.
Table 2 Adverse drug reactions occurring in two or more patients by nivolumab dose and grade
Nivolumab
1 mg/kg (n = 3) 3 mg/kg (n = 5) 10 mg/kg (n = 6) 20 mg/kg (n = 3)
SOC and PTa Grade ≥3 All grades Grade ≥3 All grades Grade ≥3 All grades Grade ≥3 All grades
Overall 0 3 1 5 0 6 1 3
Cardiac disorders
Ventricular extrasystoles 0 0 0 1 0 2 0 1
Gastrointestinal disorders
Constipation 0 0 0 1 0 2 0 0
Diarrhea 0 0 0 1 0 1 0 0
General disorders and administration site conditions
Fatigue 0 0 0 1 0 2 0 1
Malaise 0 0 0 0 0 2 0 0
Pyrexia 0 1 0 1 0 2 0 2
Investigations
Alanine aminotransferase increased 0 1 0 0 0 1 0 0
Blood albumin decreased 0 0 0 1 0 2 0 2
Blood creatinine increased 0 0 0 0 0 2 0 0
Blood lactate dehydrogenase increased 0 0 0 0 0 2 0 0
Blood thyroid stimulating hormone increased 0 0 0 1 0 1 0 0
Blood urea increased 0 0 0 0 0 1 0 1
Blood uric acid increased 0 0 0 0 0 3 0 1
C-reactive protein increased 0 0 0 1 0 1 0 0
Eosinophil count increased 0 2 0 3 0 2 0 1
Hematocrit decreased 0 0 0 1 0 2 0 0
Hemoglobin decreased 0 0 0 1 0 2 0 0
Lymphocyte count decreased 1 1 2 5 1 2
Protein total decreased 0 0 0 1 0 0 0 1
White blood cell count increased 0 1 0 0 0 1 0 1
Tri-iodothyronine free decreased 0 0 0 0 0 1 0 1
Rheumatoid factor increased 0 0 0 1 0 1 0 0
Metabolism and nutrition disorders
Decreased appetite 0 0 0 0 0 2 0 1
Skin and subcutaneous tissue disorders
Erythema 0 0 0 1 0 1 0 0
Pruritus 0 0 0 1 0 2 0 0
Rash 0 1 0 2 0 2 0 0
SOC system organ class, PT preferred term
aMedDRA SOC/PTclassification. Adverse drug reactions constituted adverse events for which a causal relationship with nivolumab could not be ruled
out
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There were no treatment-related deaths from the first dose
of the study drug to the end of the follow-up period.
During the period from the start to the end of clinical study,
no abnormal change in vital signs was observed in any sub-
ject. Clinically significant electrocardiographic abnormalities
were observed in six patients, but no clinically significant
abnormalities in chest X-ray were observed.
Safety according to anti-nivolumab antibody status
Anti-nivolumab antibody tests measured between the start and
the end of the study were positive in 2/17 patients. There were
no serious allergic reactions in any patients.
Pharmacokinetics
The serum concentration-time profiles of nivolumab after sin-
gle intravenous infusion at doses of 1–20 mg/kg are shown in
Fig. 3. The pharmacokinetic parameters following a single
dose of 1–20 mg/kg nivolumab over a period of ≥1 h are
presented in Table 3. The mean t1/2 of serum nivolumab
ranged from 13 to 21 days. The AUClast increased in a dose-
proportional manner from 1 to 20 mg/kg. While Cmax in-
creased almost dose-proportionally at nivolumab doses of 1–
10 mg/kg, the increase in Cmax was not dose-proportional at
doses of 10–20 mg/kg (Fig. 4).
Efficacy
The best overall responses are shown in Table 4, and the
duration of response in each patient is shown in Fig. 5.
Based on the RECIST guidelines (v1.0), a CR was observed
in one patient (melanoma) in the 3 mg/kg cohort and PR was
observed in one patient in each of the 1 mg/kg (colorectal
cancer) and 10 mg/kg (medullary thyroid cancer) cohorts.
Online Resource Fig. 1 shows the tumor regression in these
two patients.
Correlation of PD-L1 status with clinical response
PD-L1 expression in tumor tissue was evaluated by immuno-
histochemistry in 11 patients. High PD-L1 expression was
defined as a staining intensity relatively equal to that of a
positive control (placenta). Low PD-L1was defined as weaker
staining intensity than that of the positive control. A PR was
observed in 2/8 patients with high PD-L1 expression. An ob-
jective response was not observed in any of the patients with
low PD-L1 expression.
Table 3 Pharmacokinetic
parameters of nivolumab after a
single intravenous infusion over
≥1 h
Nivolumab dose
1 mg/kg (n = 3) 3 mg/kg (n = 5) 10 mg/kg (n = 6) 20 mg/kg (n = 3)
Cmax (μg/ml) 24.4 ± 4.5 68.8 ± 10.9 192 ± 36 214 ± 68
tmax
a (h) 3.0 (1.0–9.0) 1.0 (1.0–3.0) 3.0 (1.0–9.0) 9.0 (3.0–25)
AUClast (μg·h/ml) 4950 ± 580 12,300 ± 4500 43,900 ± 7200 67,400 ± 15,500
AUCinf (μg·h/ml) 8000 ± 1390 20,000 ± 11,300 82,700 ± 18,700 126,000 ± 62,000
t1/2 (h) 360 ± 10 320 ± 170 520 ± 270 410 ± 230
t1/2 (day) 15 ± 0 13 ± 7 21 ± 11 17 ± 9
CL (ml/h/kg) 0.127 ± 0.02 0.21 ± 0.152 0.126 ± 0.027 0.206 ± 0.143
VSS (ml/kg) 64.6 ± 6.7 69.7 ± 10.2 83.6 ± 27.4 96.8 ± 12.1
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Fig. 3 Mean serum concentration-time profiles of nivolumab after single
intravenous infusion over 1 h to Japanese patients with malignant tumors
at doses of 1 to 20 mg/kg
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Pharmacodynamics
No remarkable changes were observed in the lymphocyte sub-
set analysis, antigen immune reactivity assays using peripher-
al blood mononuclear cells, or serum cytokine and immuno-
globulin (antibody) levels during the study.
Discussion
We evaluated the safety, tolerability and pharmacokinetic pro-
files of single and multiple doses of nivolumab given to 17
Japanese patients with malignant solid tumors in this open-
label, dose-escalation study. We also assessed the efficacy and
pharmacological activity of nivolumab in these patients.
No DLTs were observed with nivolumab at any dose tested
up to 20 mg/kg, and the MTD could not be determined. The
latter result is consistent with other studies performed overseas
[23–25], although the maximum dose tested was 20 mg/kg in
our study compared with 10 mg/kg in the other studies.
ADRs were reported in all patients, but all types of
ADRs were previously described in patients treated with
nivolumab, and no new safety concerns were raised.
Grade ≥3 ADRs (lymphocyte count decreased) were ob-
served in the 3 and 20 mg/kg dose groups in our study
(20.0% and 33.3%, respectively). These were transient
and the patients recovered without treatment.
Importantly, we found no major differences in the inci-
dences or severities of ADRs among the four dose groups,
even after multiple doses of up to 20 mg/kg, thereby
confirming that nivolumab is well tolerated at doses of up to
20 mg/kg. Although the small number of patients in the
20 mg/kg cohort means these results should be interpreted
with caution, there may be positive implications for outpatient
management of ADRs, even at high doses of nivolumab.
The mean t1/2 of serum nivolumab was 13–21 days after
single doses of 1, 3, 10 or 20 mg/kg nivolumab administered
over a period of 1 h to Japanese patients with malignant solid
tumors. The AUClast of nivolumab increased almost dose-
proportionally at doses of 1–20 mg/kg. The Cmax of nivolumab
increased almost dose-proportionally at doses of 1–10 mg/kg,
but increased less than dose-proportionally at doses of 10–
20 mg/kg. This may have resulted from the wide interindividual
variability in Cmax values in the 20 mg/kg cohort.
The current study included a maximum dose of 20 mg/kg,
unlike other published studies of nivolumab, and indeed our
own unpublished study, in which we used a maximum dose of
10mg/kg. It was important to explore the effects of higher doses
of nivolumab because the MTD had not been described in prior
studies using doses of up to 10 mg/kg, and the possibility of a
flat dose was being considered. It was therefore important to
confirm the safety of a higher dose of nivolumab, and to deter-
mine whether efficacy increased at a higher dose. The latter was
not found to be the case, with no responders among the 20 mg/
kg cohort, indicating that the efficacy of nivolumab is unlikely
to increase with a dose of 20mg/kg.While our findings are from
Japanese patients, who generally have a smaller body mass than
Western populations, the pharmacokinetics and safety of
nivolumab are apparently unaffected by ethnicity (unpublished
data: Nivolumab [Anti-PD-1] BMS-936558 Ethnicity
Insensitivity Report; Bristol-Myers Squibb).
Using the RECIST criteria, we observed a CR in one patient
(melanoma) in the 3mg/kg group, and PRs in one patient each in
the 1mg/kg (colorectal cancer) and 10mg/kg (medullary thyroid
carcinoma) groups. The latter result is interesting because, to our
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Fig. 4 Relationship between doses and Cmax (a) and AUClast (b) of
nivolumab at single dose of 1 to 20 mg/kg after intravenous continuous
administration over 1 h to Japanese malignancy patients
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nivolumab in medullary thyroid carcinoma. Further trials of
nivolumab in this cancer may therefore be warranted.
As with the other studies mentioned [23–25], we also ob-
served durable responses. In one case, CR was maintained for
more than 5 years. Prolonged disease stabilization has also
been observed in prior studies of nivolumab [24, 25].
In our study, objective responses were observed in 2/8 (25%)
patients (one CR in a patient with melanoma, and a PR in
colorectal cancer) with high PD-L1 expression, but CR or PR
were not observed in patients with low PD-L1 expression.
Similar trials have shown a stronger relationship between re-
sponse and PD-L1 expression. Topalian et al. observed an ob-
jective response (either CR or PR) in 36% of patients with PD-
L1–positive tumors and in none with PD-L1–negative tumors
[25], while a systematic review of 20 trials in metastatic mela-
noma, NSCLC, and RCC patients receiving anti–PD-1/PD-L1
antibodies showed a significant decrease (53%) in the risk of
mortality in patients with malignant melanoma positive for PD-
L1, but no such response relationship was observed for NSCLC
or RCC [26]. Therefore, the use of PD-L1 as a possible bio-
marker clearly requires further investigation.
Anti-nivolumab antibody tests were performed several
times, and were positive in two patients in the single-dose
phase between study start and study discontinuation, but not
during the multiple-dose phase or extended treatment phase.
No serious allergic reactions were observed. There were no
major differences in AEs between patients positive and nega-
tive for anti-nivolumab antibodies (unpublished data:
ClinicalTrials.gov [NCT00441337]).
The PDCD1 gene was first discovered by Ishida and col-
leagues in 1992 [27]. They hypothesized that PD-1 functions
as a cell-death inducer, but other possibilities must also be
considered. For example, the PD-1 product may be a marker
for phagocytosis, or may ‘rescue’ some cells from a dying cell
population, or that PD-1 is a byproduct of programmed cell
death-induced cells [27]. Blocking PD-1 may help overcome
immune resistance to cancer by modulating both innate and
adaptive immune responses in tumors.
All patients in this study had advanced refractory solid
tumors for which no other therapy had been successful.
Tumors develop many resistance mechanisms, including local
immune suppression, induction of tolerance, and systemic
dysfunction in T-cell signaling [28–31]. Other treatments un-
der investigation for some such tumors include the anti–
CTLA-4 antibody ipilimumab, an immune-checkpoint-
pathway inhibitor that was effective in advanced melanoma
10 mg/kg (Thymic carcinoma)
3 mg/kg (Lung adenocarcinoma)
1 mg/kg (Lung adenocarcinoma)
3 mg/kg (Melanoma)
3 mg/kg (Melanoma)
10 mg/kg (Thymic carcinoma)
10 mg/kg (Thyroid cancer*)
1 mg/kg (Rectal carcinoma)
3 mg/kg (Lung adenocarcinoma)
10 mg/kg (Lung adenocarcinoma)
20 mg/kg (Rectal carcinoma)
20 mg/kg (Esophageal carcinoma)
1 mg/kg (Melanoma)
10 mg/kg (Melanoma)
20 mg/kg (Colon cancer)
10 mg/kg (Lung adenocarcinoma)
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Fig. 5 Duration of response in 17
patients in the efficacy population
between start and end of the study
The melanoma patient (indicated
in green) has had a complete
response for ≥55 months at time
of writing
Table 4 Best overall response
Nivolumab dose (mg/kg) Total CR PR SD PD
1 3 0 1 (RC) 0 2
3 5 1 (Melanoma) 0 1 (NSCLC) 3
10 6 0 1 (Thyroid cancer) 2 (Thymic cancer, NSCLC) 3
20 3 0 0 0 3
Total 17 1 2 3 11
CR complete response, RC colorectal cancer, NSCLC non-small cell lung cancer, PD progressive disease, PR
partial response, SD stable disease
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[32–34]. Combinations of these agents may provide greater
benefit than each agent alone. Nivolumab combined with
ipilimumab showed superior survival benefits in patients with
metastatic melanoma compared with ipilimumab alone [35].
Further studies of these new immunotherapeutic agents alone
or in combination are vital for the future success of treatment
of advanced refractory cancers.
The results of this study should be considered in light of its
limitations. In particular, the study enrolled a low number of
patients, and variations in clinicopathological features among
patients could have influenced the results.
Conclusions
Nivolumab administered at doses of 1, 3, 10, and 20 mg/kg
was associated with good tolerability up to the maximum
dose, with no DLTs observed and no MTD defined. In terms
of the pharmacokinetics of nivolumab, AUClast was linear at
doses of up to 20 mg/kg, and Cmax was linear at doses of up to
10 mg/kg. Nivolumab achieved CR in one patient and PR in
two patients in this Japanese population with advanced refrac-
tory malignant solid tumors. Further trials of nivolumab in a
larger patient population are warranted. Although we could
not determine the MTD, the limited efficacy of nivolumab at
20 mg/kg relative to the lower doses suggests that the maxi-
mum dose of nivolumab should be 10 mg/kg in future studies.
The dose dependency of the tumor response was not clear.
Additional studies might be necessary to establish the recom-
mended therapeutic dose in Japanese patients.
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